Pharmacokinetic enhancers for HIV drugs

Current Opinion in Investigational Drugs

Volumn 10, Issue 8, 2009, Pages 775-786

  Xu, Lianhong ^a   Desai, Manoj C ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Booster; Cytochrome P450 inhibition; Drug drug interaction; Mechanism based inhibition; Pharmacokinetic enhancer; Ritonavir

Indexed keywords

AMPRENAVIR PHOSPHATE; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APLAVIROC; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ELVITEGRAVIR; EXCIPIENT; GS 9350; INDINAVIR; INDINAVIR PLUS RITONAVIR; KETOCONAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; PF 03716539; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SPI 452; TIPRANAVIR; TMC 41629; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; AEROBIC METABOLISM; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER INJURY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; PARESTHESIA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RITONAVIR;

EID: 68649113534     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med (1998) 338(13):853-860.
2. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM et al: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. J Am Med Assoc (2008) 300(5):555-570. • Provides an overview of HIV therapeutic management.
3. 9 cells/L. Ann Intern Med (2003) 139(10):810-817.
4. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F: An updated systematic overview of triple combination therapy in antiretroviral-naïve HIV-infected adults. AIDS (2006) 20(16):2051-2064.
5. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, Allison J, Chatham A, Raper JL, Kaslow RA, Saag MS et al: Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS (2008) 22(15):1951-1960.
6. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM: Better adherence with once-daily antiretroviral regimens: A meta-analysis. Clin Infect Dis (2009) :doi:10.1086/596482.
7. Patick A, Potts K: Protease inhibitors as antiviral agents. Clin Microbiol Rev (1998) 11(4):614-627.
8. Flexner C: HIV-protease inhibitors. New Engl J Med (1998) 338(18):1281-1292.
9. Norvir: Abbott Laboratories, North Chicago, IL, USA (2008). www.rxabbott.com/pdf/norpi2a.pdf
10. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV: Pharmacodynamics of HIV-1 protease inhibitors. Clin Infect Dis (2000) 30 (Suppl 2):S151-S159.
11. Gerber JG: Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis (2000) 30 (Suppl 2):S123-S129.
12. Barry M, Mulcahy F, Merry C, Gibbons S, Back D: Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmcokinet (1999) 36(4):289-304.
13. Moyle G: Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read (2001) 11(2):87-98.
14. Kumar GN, Rodrigues AD, Buko AM, Denissen JF: Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther (1996) 277(1):423-431. • Presents data on the metabolism profile of ritonavir in vitro.
15. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E et al: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 41(3): 654-660. • Presents the first preliminary SAR data on CYP3A inhibition of ritonavir.
16. Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM: Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther (1998) 63(4):453-464. • The first demonstration that ritonavir boosts the PKs of coadministered PIs.
17. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM, Sun E: Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother (1998) 42(11):2784-2791.
18. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D, Markowitz M, Follansbee S, Angel JB et al: Ritonavir and saquinavir combination therapy for the treatment of HIV infections. AIDS (1999) 13(2):213-224.
19. Burger DM, Hugen PWH, Aarnoutse RE, Dieleman JP, Prins JM, van der Poll T, ten Veen JH, Mulder JW, Meenhorst PL, Blok WL, van der Meer JTM et al: A retrospective, cohort-based survey of patients using twice-daily indinavir+ritonavir combinations: Pharmacokinetics, safety, and efficacy JAIDS (2001) 26(3):218-224.
20. Moyle GJ, Back D: Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med (2001) 2(2):105-113.
21. Cooper CL, van Heeswijk RPG, Gallicano K, Cameron DW: A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis (2003) 36(12):1585-1592.
22. Becker SL: The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin Investig Drugs (2003) 12(3):401-412.
23. Gallant JE: Protease-inhibitor boosting in the treatmentexperienced patient. AIDS Rev (2004) 6(4):226-233.
24. Youle M: Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother (2007) 60(6):1195-1205.
25. Busse KH, Penzak SR: Pharmacological enhancement of protease inhibitor with ritonavir: An update. Expert Rev Clin Pharmacol (2008) 1(4):533-545. •• The latest review on ritonavir-boosted PIs at the time of publication.
26. Viracept: Agouron Pharmaceuticsl Inc, La Jolla, CA, USA (2007). www.pfizer.com/files/products/ppi-viracept.pdf
27. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents: Department of Health and Human Services (2008). www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
28. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, Gerber N: Metabolism of the human immunodeficiency virus protease inhibitor indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos (1998) 26(6):552-561.
29. von Moltke LL, Durol AL, Duan SX, Greenblatt DJ: Potent mechanism based inhibition of human CYP3A in vitro by amprenavir and ritonavir: Comparison with ketoconazole. Eur J Clin Pharmacol (2000) 56(3):259-261.
30. Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, LeCluyse E, Solon E, Brennan JM, Benedek IH et al: Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos (2003) 31(9): 1170-1175.
31. Ernest CS 2nd, Hall SD, Jones DR: Mechanism-based inactivation of CYP3A by HIV protease inhibitor. J Pharmacol Exp Ther (2005) 312(2):583-591. • Characterization of the inactivation kinetics of ritonavir and of other HIV PIs, such as indinavir and saquinavir.
32. Obach RS, Walsky RL, Venkatakrishnan K: Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interations. Drug Metab Dispos (2007) 35(2):246-255. • Discusses the mechanism-based inactivation of CYP and the prediction of drug-drug interactions for mechanism-based CYP inactivators in vivo.
33. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet (2005) 44(3): 279-304. • Describes potential problems associated with the use of mechanism-based CYP inhibitors.
34. Fontana E, Dansette PM, Poli SM: Cytochrome P450 enzymes mechanism based inhibitors: Common sub-structures and reactivity. Curr Drug Metabolism (2005) 6(5):413-454. • Discusses potential mechanistic details governing CYP mechanismbased inhibition and potential problems associated with its use.
35. Johnson WW: Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: Therapeutic relevance. Drug Metab Rev (2008) 40(1):101-147. • Summarizes the catalytic efficiencies of drugs that inactivate CYP enzymes and discusses their clinical relevance.
36. Murray BP: Mechanism-based inhibition of CYP3A4 and other cytochromes P450. Ann Rep Med Chem (2009) 44: in press.
37. Mathias AA, West S, Hui J, Kearney BP: Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther (2009) 85(1):64-70.
38. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC et al: P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics (1996) 6(1):1-42.
39. Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev (1997) 29 (1-2): 413-580.
40. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB: The human CYP3A subfamily: Practical considerations. Drug Metab Rev (2000) 32 (3-4) :339-361.
41. Rendic S: Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev (2002) 34(1): 83-448.
42. Sulkowski MS: Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis (2004) 38 (Suppl 2):S90-S97. • Discusses hepatotoxicity events related to the use of HIV PIs.
43. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc (2000) 283(1): 74-80.
44. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD: Hepatotoxicity associated with the antiviral therapy (ART) containing protease inhibitor (PI) with or without pharmacokinetic boosting by low-dose ritonavir (RTV). Hepatology (2003) 38 (Suppl 1) :698A.
45. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 18(17):2277-2284.
46. Jevtović Dj, Ranin J, Salemović D, Pesić I, Dragović G, Zerjav S, Djurković-Djaković O: The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART. Biomed Pharmacother (2008) 62(1):21-25.
47. Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitor. Circulation (1999) 100(7):700-705.
48. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V et al: A shortterm study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med (1995) 333(23):1528-1533.
49. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard LM, Ho DD: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 333(23):1534-1539.
50. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12(7):F51-F58.
51. Gatti G, Di Biagio A, Casazza R, de Pascalis C, Basetti M, Cruciani M, Vella S, Basetti D: The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring. AIDS (1999) 13(15):2083-2089.
52. van Heeswijk RPG, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JMA, Beijnen JH, Hoetelmans RMW: Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals. A pharmacokinetic pilot study. AIDS (2000) 14(9):F103-F110.
53. Shafran SD, Mashinter LD, Roberts SE: The effects of low-dose ritonavir monotherapy on fasting serum lipid. HIV Med (2005) 6(6):421-425. •• Demonstrates that ritonavir at low doses is associated with lipid disturbances.
54. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis (2003) 37(5):613-627.
55. Dresser GK, Spence JD, Bailey DG: Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet (2000) 38(1):41-57. •• Discusses potential problems associated with CYP inhibition.
56. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD: Cytochrome P450 enzymes and transporters induced by anti-HIV protease inhibitors in human hepatocytes: Implication for predicting clinical drug interactions. Drug Metab Dispos (2007) 35(10):1853-1859.
57. Wang H, LeCluyse EL: Role of orphan nuclear receptors in the regulation of drug-metabolizing enzymes. Clin Pharmacokinet (2003) 42(15):1331-1357. • An extensive review of modulators, agonist and antagonists of orphan nuclear receptors and potential drug-drug interactions associated with them.
58. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Bäckman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A: Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA (1998) 95(21):12208-12213.
59. Kharasch ED, Mitchell D, Coles R, Blanco R: Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother (2008) 52(5):1663-1669.
60. Foisy MM, Yakiwchuk EM, Hughes CA: Induction effects of ritonavir: Implications for drug interactions. Ann Pharmacother (2008) 42(7):1048-1059. • Reviews the induction effects of ritonavir and drug-drug interactions associated with its use.
61. Kaletra (lopinavir/ritonavir) tablets: Abbott Laboratories, North Chicago, IL, USA (2008). www.rxabbott.com/pdf/kaletratabpi.pdf
62. The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects: NATAP, New York, NY, USA (2008). www.natap.org/2008/InterHIV/ InterHIV-46.htm
63. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Zhong L, Cheng AK, McColl D et al: Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J Acquir Immune Defic Syndr (2006) 43(1):1-5.
64. Adkison KK, Shachoy-Clark A, Fang L, Lou Y, Otto VR, Berrey MM, Piscitelli SC: The effects of ritonarvir and lopinavir/ritonavir on the pharmacokinectics of a novel CCR5 antagonist, aplaviroc, in healthy subjects. Br J Clin Pharmacol (2006) 62(3):336-344.
65. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ: Effects of CYP3A4 inducers with and without CYP3A4 inhibitor on the pharmacokinetics for maraviroc in healthy volunteers. Br J Clin Pharmacol (2008) 65 (Suppl 1) :38-46.
66. Pozniak AL, Boffito M, Russell D, Ridgway C, Muirhead G: A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Br J Clin Pharmacol (2008) 65 (Suppl 1) :54-59.
67. Selzentry (maraviroc) tablets: Pfizer Inc, New York, NY, USA (2008). media.pfizer.com/files/products/uspi-maraviroc.pdf
68. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Clin Pharmacokinet (2000) 38(2):111-180.
69. Boxenbaum H: Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: Determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci (1999) 2(2):45-52.
70. Pearson JT, Hill JJ, Swank J, Isoherranen N, Kunze KL, Atkins WM: Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. Biochemistry (2006) 45(20):6341-6353.b
71. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM: Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol (1994) 151(2):485-491.
72. Grub S, Bryson H, Goggin T, Lüdin E, Jorga K: The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: Comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol (2001) 57(2):115-121.
73. Autar RS, Wit FW, Sankote J, Sutthichom D, Kimenai E, Hassink E, Hill A, Cooper DA, Phanuphak P, Lange JM, Burger DM et al: Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. AIDS (2007) 21(12):1535-1539.
74. Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, Surber BW: Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos (1997) 25(4):489-501.
75. Mathias AA, Lee M, Callebaut C, Xu L, Tsai L, Murray B, Liu H, Yale K, Warren D, Kearney BP: GS-9350: A pharmaco-enhancer without anti-HIV activity. Conference on Retroviruses and Opportunistic Infections (2009) 16:Abs 40. • Presented the first PK data of GS-9350 and elvitegravir use in humans.
76. Schueller L, Baert L, Lachau-Durand S, Borghys H, Clessens E, Van Den Mooter G, Van Gyseghem E, Jonckers TH, Van Remoortere P, Wigerinck P, Rosier J: Dog model with implanted pump to test boosters for antiretroviral medication. Int J Pharm (2008) 355 (1-2) :45-52.
77. Gulnik S, Eissenstat M, Afonina E, Lutke D, Erickson J, Dagger R, Wynne B, Guttendorf R: Preclinical and early clinical evaluation of SPI-452, a new pharmacokinetic enhancer. Conference on Retroviruses and Opportunistic Infections (2009) 16:Abs 41. • Presented the first data demonstrating SPI-452 PK boosting of coadministered PIs.
78. Sequoia Pharmaceuticals Inc: Sequoia Pharmaceuticals presents in vitro and first-in-human data supporting further development of SPI-256, a novel investigational protease inhibitor. Press Release (2008): October 26.
79. No author listed: Technology Briefng: A repelling story. BioCentury, The Bernstein Report (2007):A13.
80. Clinical Trials: Bioavailability Systems LLC, Cocoa Beach, FL, USA (2007). www.bioavailsys.com/ClinicalTrials.htm
81. Li F, Kulkarni A, Pauletti G, Desai P: Influence of BAS 100, a spiro-ortho-ester, isolated from grapefruit juice on the activity and expression of drug metabolizing enzymes and transporters. Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, CA, USA (2007).
82. Li F: Investigation of BAS 100, a naturally occurring CYP3A inhibitor, as a bioavailability boosting agent. PhD thesis, University of Cincinnati (2007). www.ohiolink.edu/etd/view.cgi?acc-num=ucin1195794592